Comparison the effects of Empaglifluzin-linagliptin and Dapaglifluzin-linagliptin on HbA1c ? LDL and Albuminuria in patients with T2DM
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes.
- Registration Number
- IRCT20221221056889N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Having type 2 diabetes
Hb A1c above 7 and below 11
No acute hospitalization conditions
Age between 30 and 75 years
Patients with albuminuria
Not taking the drug beforehand
Exclusion Criteria
Acute hospitalization conditions
Pre-medication
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main outcome of this study is urine microalbuminuria, which is considered as the main indicator of diabetic nephropathy, LDL and HbA1c. This result is evaluated by spot urine and blood samples at the beginning of the study, three months after the start of the treatment. Timepoint: At the beginning of the study and three months after the start of treatment. Method of measurement: It is evaluated by spot urine and blood samples at the beginning of the study and three months after the start of the treatment.
- Secondary Outcome Measures
Name Time Method Other outcomes included in the researcher's checklist (attached at the end of the proposal), such as FBS, GFR, and lipid profile, are evaluated by the patient's blood test at the beginning of the study, and after the completion of the treatment period, i.e., three months after the start of the treatment. Timepoint: The beginning of the study and three months after the start of treatment. Method of measurement: By testing the patient's blood.